Based on the key indicators related to Atea Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Atea Pharmaceuticals may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At this time, Atea Pharmaceuticals' Accumulated Other Comprehensive Income is relatively stable compared to the past year. As of 02/02/2025, Non Current Liabilities Other is likely to grow to about 7.2 M, while Other Current Liabilities is likely to drop slightly above 20 M. Key indicators impacting Atea Pharmaceuticals' financial strength include:
Investors should never underestimate Atea Pharmaceuticals' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Atea Pharmaceuticals' cash flow, debt, and profitability to make informed and accurate decisions about investing in Atea Pharmaceuticals.
Net Income
(116.24 Million)
Atea
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Investments
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Operating Activities
Issuance Of Capital Stock
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Net Tangible Assets
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Capital Stock
Non Current Liabilities Other
Net Working Capital
Short Term Debt
Common Stock
Property Plant Equipment
Short Long Term Debt Total
Short Term Investments
Capital Lease Obligations
Net Interest Income
Interest Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Tax Provision
Probability Of Bankruptcy
Understanding current and past Atea Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Atea Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Atea Pharmaceuticals' assets may result in an increase in income on the income statement.
Atea Pharmaceuticals competes with Immix Biopharma, Hepion Pharmaceuticals, Enveric Biosciences, Elevation Oncology, and Ocean Biomedical. Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. Atea Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 63 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Atea Pharmaceuticals Key Income Statement Accounts
The reason investors look at the income statement is to determine what Atea Pharmaceuticals' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Atea Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Atea Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Atea Pharmaceuticals competition to find correlations between indicators driving Atea Pharmaceuticals's intrinsic value. More Info.
Atea Pharmaceuticals is rated second in return on equity category among its peers. It is number one stock in return on asset category among its peers . At this time, Atea Pharmaceuticals' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Atea Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Atea Pharmaceuticals Systematic Risk
Atea Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Atea Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Atea Pharmaceuticals correlated with the market. If Beta is less than 0 Atea Pharmaceuticals generally moves in the opposite direction as compared to the market. If Atea Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Atea Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Atea Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Atea Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Atea Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Atea Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Atea Pharmaceuticals growth as a starting point in their analysis.
Atea Pharmaceuticals February 2, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Atea Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Atea Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Atea Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Atea Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Atea Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Atea Pharmaceuticals' price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.